Cathepsin D Drives the Formation of Hybrid Insulin Peptides Relevant to the Pathogenesis of Type 1 Diabetes

Samantha A. Crawford(University of Colorado Anschutz Medical Campus), Timothy A. Wiles(University of Colorado Anschutz Medical Campus), Janet M. Wenzlau(University of Colorado Anschutz Medical Campus), Roger Powell(University of Colorado Anschutz Medical Campus), Gene Barbour(University of Colorado Anschutz Medical Campus), Mylinh Dang(University of Colorado Anschutz Medical Campus), Jason Groegler(University of Colorado Anschutz Medical Campus), Jessie M. Barra(University of Alabama at Birmingham), KaLia Burnette(University of Alabama at Birmingham), Anita C. Hohenstein(University of Colorado Anschutz Medical Campus), Rocky L. Baker(University of Colorado Anschutz Medical Campus), Hubert M. Tse(University of Alabama at Birmingham), Kathryn Haskins(University of Colorado Anschutz Medical Campus), Thomas Delong(University of Colorado Anschutz Medical Campus)
Diabetes
August 30, 2022
Cited by 48Open Access
Full Text

Abstract

Hybrid insulin peptides (HIPs) form in pancreatic β-cells through the formation of peptide bonds between proinsulin fragments and other peptides. HIPs have been identified in pancreatic islets by mass spectrometry and are targeted by CD4 T cells in patients with type 1 diabetes (T1D) as well as by pathogenic CD4 T-cell clones in nonobese diabetic (NOD) mice. The mechanism of HIP formation is currently poorly understood; however, it is well established that proteases can drive the formation of new peptide bonds in a side reaction during peptide bond hydrolysis. Here, we used a proteomic strategy on enriched insulin granules and identified cathepsin D (CatD) as the primary protease driving the specific formation of HIPs targeted by disease-relevant CD4 T cells in T1D. We also established that NOD islets deficient in cathepsin L (CatL), another protease implicated in the formation of disease-relevant HIPs, contain elevated levels of HIPs, indicating a role for CatL in the proteolytic degradation of HIPs. In summary, our data suggest that CatD may be a therapeutic target in efforts to prevent or slow the autoimmune destruction of β-cells mediated by HIP-reactive CD4 T cells in T1D.


Related Papers